Rigel Pharmaceuticals Bolsa (NASDAQ: RIGL)

Últimas noticias sobre Rigel Pharmaceuticals (NASDAQ:RIGL) Bolsa

Rigel Pharmaceuticals

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals Inc

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Buy and maintains $57 price target.

News

Price Target

Reiteration

Analyst Ratings

RIGL

HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target

<ul>
<li>Preliminary fourth quarter 2024 total revenue of approximately $57.6 million which includes TAVALISSE&#xAE; net product sales of $31.0 million, REZLIDHIA&#xAE; net product sales of $7.4 million and GAVRETO&#xAE; net product sales of $8.1 million</li>
<li>R289 granted Orphan Drug designation by the FDA for the treatment of MDS</li>
<li>Rigel anticipates 2025 total revenue of approximately $200 to $210 million</li>
</ul>
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>), a commercial stage biotechnology company focused on hematologic disorders and cancer, today provided a business update including preliminary total revenue and net product sales for the fourth quarter of 2024, ongoing activity from the commercial business and development pipeline, and its financial outlook for 2025.

Biotech

Guidance

General

Rigel Reports Q4 2024 Revenue Of $57.6M With TAVALISSE $31M, REZLIDHIA $7.4M, GAVRETO $8.1M; R289 Receives FDA Orphan Drug Status For MDS; 2025 Revenue Projected At $200M-$210M

R289 was previously granted&nbsp;Fast Track designation by the FDA for the treatment of patients with previously-treated transfusion dependent lower-risk MDS.

Rigel Pharmaceuticals Says FDA Granted Orphan Drug Designation To R289 For Treatment Of Myelodysplastic Syndromes

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 200 points on Tuesday.
The Dow traded up 0.53% to 43,132.84 while the NASDAQ climbed 1.05% to 19,972.38. The S&amp;P 500 also rose, gaining, 0.78% to 6,020.96.
Check This Out: <a href="https://www.benzinga.com/24/12/42669200/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Utilities Stocks With Over 4% Dividend Yields</a>
Leading and Lagging Sectors Consumer discretionary shares jumped by 1.8% on Tuesday.
In trading on Tuesday, health care shares rose by just 0.1%.
Top Headline
The composite manufacturing index in the U.S. Fifth District increased to -10 in December compared to a reading of -14 in the previous month.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Greenfire Resources Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFR#NYSE">GFR</a>) shares shot up 13% to $7.00 after Waterous Energy Fund acquired 9,311,424 common shares and 2,654,179 common share purchase warrants of the company.</li>
<li>Shares of Carbon Revolution Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREV#NASDAQ">CREV</a>)got a boost, surging 103% to $7.87 after the company announced it has reached an agreement with OIC for a further $25 million in financing to support the ongoing liquidity of the business.</li>
<li>Jet.AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JTAI#NASDAQ">JTAI</a>) shares were also up, gaining 73% to $5.91 after the company announced it launched &#8220;Ava&#8221; an agentic AI model for private jet booking.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Canoo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOEV#NASDAQ">GOEV</a>) shares dropped 8% to $1.4606.</li>
<li>Shares of Limoneira Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMNR#NASDAQ">LMNR</a>) were down 8% to $24.80 after reporting fourth-quarter results.</li>
<li>Rigel Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) was down, falling 7% to $16.00.</li>
</ul>
Commodities In commodity news, oil traded up 1.5% to $70.28 while gold traded up 0.1% at $2,630.20.
Silver traded up 0.1% to $30.205 on Monday, while copper rose 0.6% to $4.1085.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.17%, Germany's DAX fell 0.18% and France's CAC 40 rose 0.14%. Spain's IBEX 35 Index rose 0.33%, while London's FTSE 100 rose 0.42%.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 falling 0.32%, Hong Kong's Hang Seng Index gaining 1.08%, China's Shanghai Composite Index gaining 1.26% and India's BSE Sensex falling 0.09%.
Economics
<ul>
<li>U.S. Redbook index increased 5.9% year-over-year in the latest week, following a prior reading of 4.8% gain.</li>
<li>The composite manufacturing index in the U.S. Fifth District increased to -10 in December compared to a reading of -14 in the previous month.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42669068/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

CREV

GOEV

JTAI

LMNR

Dow Jumps Over 200 Points, Crude Oil Gains 1.5%

WIIM

Rigel Pharmaceuticals shares are trading lower after B. Riley Securities cut its price target on the stock from $27 to $20.

Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Neutral and raises the price target from $15 to $25.

Cantor Fitzgerald Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $25

B. Riley Securities analyst Kalpit Patel maintains Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Neutral and lowers the price target from $27 to $20.

B. Riley Securities Maintains Neutral on Rigel Pharmaceuticals, Lowers Price Target to $20

<ul>
<li>R289 was generally well tolerated and demonstrated signs of preliminary clinical activity in elderly heavily pretreated LR-MDS patients</li>
<li>RBC-TI/HI-E responses occurred in 40% of evaluable TD patients receiving R289 doses ≥500 mg QD</li>
</ul>
SOUTH SAN FRANCISCO, Calif., Dec. 9, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced initial&nbsp;data from its ongoing Phase 1b study evaluating R2891, an oral prodrug of R835, a potent and selective dual inhibitor of IRAK1 and IRAK4, in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (LR-MDS). The data is being&nbsp;presented today by Dr. Guillermo Garcia-Manero (Poster #: 4595) at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 7-10, in San Diego, California and virtually.&nbsp;

Rigel Pharmaceuticals Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 In LR-MDS At The 66th ASH Annual Meeting; R289 Was Generally Well Tolerated And Demonstrated Signs Of Preliminary Clinical Activity In Elderly Heavily Pretreated LR-MDS Patients

B. Riley Securities analyst Kalpit Patel maintains Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Neutral and raises the price target from $17 to $27.

B. Riley Securities Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $27

Rigel Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to R289 for the treatment of patients with previously-treated transfusion dependent lower-risk myelodysplastic syndrome (LR-MDS). R2891, Rigel's potent and selective dual inhibitor of IRAK1 and IRAK4, is being studied in an ongoing Phase 1b study evaluating the safety, tolerability, pharmacokinetics and preliminary activity in patients with LR-MDS who are relapsed or refractory to prior therapies.

Rigel Announces R289 Granted Fast Track Designation By The FDA For Lower-Risk MDS

Piper Sandler analyst Allison Bratzel maintains Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Neutral and raises the price target from $15 to $23.

Piper Sandler Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $23

Rigel Pharmaceuticals shares are trading higher Citigroup maintained a Buy rating on the stock and raised its price target from $40 to $49.

Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Buy and raises the price target from $40 to $49.

Citigroup Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $49

Rigel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.

<h3>Gainers</h3>
<ul>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock rose 39.8% to $0.36 during Friday's regular session. The market value of their outstanding shares is at $2.2 million. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) stock increased by 33.57% to $24.11. The market value of their outstanding shares is at $2.1 billion. As per the press release, Q3 earnings came out today. </li>
<li>Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) stock moved upwards by 32.05% to $20.39. The market value of their outstanding shares is at $358.7 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) shares increased by 21.59% to $3.2. The company's market cap stands at $83.1 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock rose 19.31% to $0.45. The market value of their outstanding shares is at $6.0 million. </li>
<li>Inhibikase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) stock increased by 18.7% to $3.3. The company's market cap stands at $217.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock fell 48.1% to $0.74 during Friday's regular session. The market value of their outstanding shares is at $14.1 million. </li>
<li>Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) stock fell 41.11% to $14.47. The company's market cap stands at $1.6 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) shares fell 37.31% to $4.92. The market value of their outstanding shares is at $695.7 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) stock fell 36.6% to $3.67. The company's market cap stands at $381.8 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) stock declined by 32.08% to $1.9. The market value of their outstanding shares is at $779.7 million. The company's, Q3 earnings came out yesterday. </li>
<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) stock decreased by 29.23% to $0.69. The market value of their outstanding shares is at $80.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALVR

BNOX

FTRE

MRVI

NOTV

PRPH

RVNC

TIVC

12 Health Care Stocks Moving In Friday's Intraday Session

Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.03 by 2233.33 percent. The company reported quarterly sales of $55.307 million which beat the analyst consensus estimate of $41.927 million by 31.91 percent. This is a 96.58 percent increase over sales of $28.134 million the same period last year.

Earnings Beats

Rigel Pharmaceuticals Q3 2024 GAAP EPS $0.70 Beats $0.03 Estimate, Sales $55.307M Beat $41.927M Estimate

Rigel Pharmaceuticals, Inc. ("Rigel") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced it is issuing a Dear Health Care Provider (DHCP) letter related to a new safety signal for GAVRETO&#xAE; (pralsetinib) after consultation with the U.S. Food and Drug Administration (FDA). GAVRETO is for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by a FDA approved test and adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). The DHCP letter has been posted to the GAVRETO Healthcare Provider website at <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4286741-1&amp;h=3852763292&amp;u=https%3A%2F%2Fgavreto-hcp.com%2F&amp;a=www.gavreto-hcp.com">www.gavreto-hcp.com</a>.

Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter For GAVRETO After Consultation With The U.S. FDA  For The Treatment Of Adult Patients With Metastatic Rearranged During Transfection

Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs

B. Riley raised the firm's price target on Rigel Pharmaceuticals (RIGL) to $27 from $17 and keeps a Neutral rating on the shares. The shares rallie...

Rigel Pharmaceuticals price target raised to $27 from $17 at B. Riley

Rigel Pharmaceuticals (RIGL) announced initial data from its ongoing Phase 1b study evaluating R2891, an oral prodrug of R835, a potent and selecti...

Rigel Pharmaceuticals announces initial data from Phase 1b study of R289

In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Hold rating on Rigel (RIGL – Research Report), with a price targ...

Cantor Fitzgerald Remains a Hold on Rigel (RIGL)

Cantor Fitzgerald raised the firm's price target on Rigel Pharmaceuticals (RIGL) to $25 from $15 and keeps a Neutral rating on the shares. Rigel an...

Rigel Pharmaceuticals price target raised to $25 from $15 at Cantor Fitzgerald

Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents

The FDA granted Rigel Pharmaceuticals (RIGL) orphan status for its treatment of myelodysplastic syndromes. Published first on TheFly – the ultimate...

Rigel granted orphan status for myelodysplastic syndromes treatment

Rigel receives orphan drug designation by the FDA for its myelodysplastic syndrome treatment

Rigel Pharmaceuticals (RIGL) announced that the U.S. Food and Drug Administration has granted Orphan Drug designation to R289 for the treatment of ...

Comments

Rigel Pharmaceuticals

Noticias

Últimas noticias sobre Rigel Pharmaceuticals (NASDAQ:RIGL) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL